A safety, pharmacokinetic and pharmacodynamic investigation of deferasirox (Exjade®, ICL670) in patients with transfusion-dependent anemias and iron-overload: a Phase I study in Japan-Reference-Cited by-同舟云学术

A safety, pharmacokinetic and pharmacodynamic investigation of deferasirox (Exjade®, ICL670) in patients with transfusion-dependent anemias and iron-overload: a Phase I study in Japan

Published:2008-07 Issue:1 Volume:88 Page:73-81
ISSN:0925-5710
Container-title:International Journal of Hematology
language:en
Short-container-title:Int J Hematol

Author:

Miyazawa Keisuke,Ohyashiki Kazuma,Urabe Akio,Hata Tomoko,Nakao Shinji,Ozawa Keiya,Ishikawa Takayuki,Kato Junji,Tatsumi Yoichi,Mori Hiraku,Kondo Midori,Taniguchi Junsuke,Tanii Hiromi,Rojkjaer Lisa,Omine Mitsuhiro

Publisher

Springer Science and Business Media LLC

Subject

Hematology

Link

http://link.springer.com/content/pdf/10.1007/s12185-008-0115-2.pdf

Reference21 articles.

1. Olivieri N. Thalassaemia: clinical management. Baillieres Clin Haematol. 1998;11:147–62.

2. Jansen AJ, Essink-Bot ML, Beckers EA, Hop WC, Schipperus MR, Van Rhenen DJ. Quality of life measurement in patients with transfusion-dependent myelodysplastic syndromes. Br J Haematol. 2003;121:270–4.

3. Lee MT, Piomelli S, Granger S, et al. Stroke prevention trial in sickle cell anemia (STOP): extended follow-up and final results. Blood. 2006;108:847–52.

4. McLaren GD, Muir WA, Kellermeyer RW. Iron overload disorders: natural history, pathogenesis, diagnosis, and therapy. Crit Rev Clin Lab Sci. 1983;19:205–66.

5. Kushner JP, Porter JP, Olivieri NF. Secondary iron overload. Hematology Am Soc Hematol Educ Program. 2001;47–61.

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Iron chelator deferasirox inhibits NF-κB activity in hepatoma cells and changes sorafenib-induced programmed cell deaths;Biomedicine & Pharmacotherapy;2022-09

2. Characterisation of individual ferritin response in patients receiving chelation therapy;British Journal of Clinical Pharmacology;2022-03-26

3. Cu2+-induced quenching and recovery of the luminescence of dopamine-conjugated carbon dots for sensing deferasirox in plasma;Sensors and Actuators B: Chemical;2020-05

4. Successful Introduction of Peritoneal Dialysis in an End-stage Renal Failure Patient with Idiopathic Aplastic Anemia;Internal Medicine;2020-03-01

5. ABCC2 c.-24 C>T single-nucleotide polymorphism was associated with the pharmacokinetic variability of deferasirox in Chinese subjects;European Journal of Clinical Pharmacology;2019-11-01